BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Molecular Neurobiology

• Publication date

  2012-06-05

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s12035-012-8284-7PMID 22669612
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Loss of correlations among proteins in brains of the Ts65Dn mouse model of down syndrome.

  2012cited by this paper
• Stimulated neuronal expression of brain-derived neurotrophic factor by Neurotropin.

  2010cited by this paper
• Serum neutrophil gelatinase-B associated lipocalin (NGAL) levels in Down’s syndrome patients

  2010cited by this paper
• Age-related changes in plasma levels of BDNF in Down syndrome patients

  2010cited by this paper
• Genome-wide association scan for five major dimensions of personality

  2010cited by this paper
• Early Pharmacotherapy Restores Neurogenesis and Cognitive Performance in the Ts65Dn Mouse Model for Down Syndrome

  2010cited by this paper
• Engineering DYRK1A overdosage yields Down syndrome-characteristic cortical splicing aberrations.

  2010cited by this paper
• Green Tea Polyphenols Rescue of Brain Defects Induced by Overexpression of DYRK1A

  2009cited by this paper
• Brain-derived neurotrophic factor: a newly described mediator of angiogenesis.

  2007cited by this paper
• Use of health care guidelines in patients with Down syndrome by family physicians across Canada.

  2007cited by this paper
• Classification of human chromosome 21 gene-expression variations in Down syndrome: impact on disease phenotypes.

  2007cited by this paper
• Dissecting the human BDNF locus: Bidirectional transcription, complex splicing, and multiple promoters

  2007cited by this paper
• NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21

  2006cited by this paper
• DYRK1A (Dual-Specificity Tyrosine-Phosphorylated and -Regulated Kinase 1A): A Gene with Dosage Effect During Development and Neurogenesis

  2006cited by this paper
• Association of a functional BDNF polymorphism and anxiety-related personality traits

  2005cited by this paper
• The impact of age, weight and gender on BDNF levels in human platelets and plasma.

  2004cited by this paper
• Brain-derived neurotrophic factor as a drug target for CNS disorders

  2004cited by this paper
• Chromosome 21 and Down syndrome: from genomics to pathophysiology

  2004cited by this paper
• Brain-Derived Neurotrophic Factor Activation of NFAT (Nuclear Factor of Activated T-Cells)-Dependent Transcription: A Role for the Transcription Factor NFATc4 in Neurotrophin-Mediated Gene Expression

  2003cited by this paper
• Frontal cortex BDNF levels correlate with working memory in an animal model of Down syndrome.

  2003cited by this paper
• Brain-derived Neurotrophic Factor Is Stored in Human Platelets and Released by Agonist Stimulation

  2002cited by this paper
• Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.

  2001cited by this paper
• Protein Kinase Dyrk1 Activates cAMP Response Element-binding Protein during Neuronal Differentiation in Hippocampal Progenitor Cells*

  2001cited by this paper
• Vascular endothelial cells synthesize and secrete brain‐derived neurotrophic factor

  2000cited by this paper
• Activated Human T Cells, B Cells, and Monocytes Produce Brain-derived Neurotrophic Factor In Vitro and in Inflammatory Brain Lesions: A Neuroprotective Role of Inflammation?

  1999cited by this paper
• Neurotrophin-dependent modulation of glutamatergic synaptic transmission in the mammalian CNS.

  1998cited by this paper
• Neurotrophin and neurotrophin receptors in vascular smooth muscle cells. Regulation of expression in response to injury.

  1995cited by this paper
• Cognitive impairment in adults with Down's syndrome

  1994cited by this paper

• Vertebrate and Invertebrate Animal Models for the Study of Down Syndrome

  2025cites this paper
• Unique Pathology in the Locus Coeruleus of Individuals with Down Syndrome

  2024cites this paper
• Prenatal treatment with preimplantation factor improves early postnatal neurogenesis and cognitive impairments in a mouse model of Down syndrome

  2024cites this paper
• Over‐expression of Dyrk1A affects bleeding by modulating plasma fibronectin and fibrinogen level in mice

  2023cites this paper
• DYRK1A and Activity-Dependent Neuroprotective Protein Comparative Diagnosis Interest in Cerebrospinal Fluid and Plasma in the Context of Alzheimer-Related Cognitive Impairment in Down Syndrome Patients

  2022cites this paper
• Down syndrome is an oxidative phosphorylation disorder

  2021cites this paper
• Astrocytes in Down Syndrome Across the Lifespan

  2021cites this paper
• Ultrastructural and dynamic studies of the endosomal compartment in Down syndrome

  2020cites this paper
• Hypothesis and Theory: Circulating Alzheimer's-Related Biomarkers in Type 2 Diabetes. Insight From the Goto-Kakizaki Rat

  2019cites this paper
• The burden of trisomy 21 disrupts the proteostasis network in Down syndrome

  2017cites this paper
• Early neurotrophic pharmacotherapy rescues developmental delay and Alzheimer’s-like memory deficits in the Ts65Dn mouse model of Down syndrome

  2017cites this paper
• Aerobic exercise and a BDNF-mimetic therapy rescue learning and memory in a mouse model of Down syndrome

  2017cites this paper
• Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer’s disease

  2017cites this paper
• Intracisternal Gtf2i Gene Therapy Ameliorates Deficits in Cognition and Synaptic Plasticity of a Mouse Model of Williams-Beuren Syndrome.

  2015cites this paper
• Plasma DYRK1A as a novel risk factor for Alzheimer's disease

  2014cites this paper
• The Akt-mTOR pathway in Down's syndrome: the potential use of rapamycin/rapalogs for treating cognitive deficits.

  2014cites this paper
• Validation of microarray data in human lymphoblasts shows a role of the ubiquitin-proteasome system and NF-kB in the pathogenesis of Down syndrome

  2013cites this paper
• Protein profiles in Tc1 mice implicate novel pathway perturbations in the Down syndrome brain

  2013cites this paper